Benoit Gravel has 30 years of experience in the pharmaceutical industry from his work at Rhône-Poulenc, Aventis and Sanofi. Mr. Gravel has held several commercial executive positions in Canada, including vice-president diabetes & specialized care patient centered unit at Sanofi. He began his career as an economist in the energy and transportation industries.

Stephen Nelson served as senior vice president, portfolio manager, and investment advisor with TD Wealth Private Investment Advice. Mr. Nelson manages over $6.5 billion in investment assets as of June 2026 and has been a member of TD Waterhouse’s President Club for the past 25 years. He has also served as a director for a number of private companies.

Nancy Phelan is a recognized life sciences thought leader, digital pioneer, and change agent with 25+ years of experience in commercial strategy and operations. Ms Phelan currently serves as Senior Vice President, Marketing and Analytics at Phathom Pharmaceuticals, a biopharmaceutical company focused on acid-related gastrointestinal disorders, and previously served as Senior Vice President, Customer Engagement at Trinity Life Sciences, and SVP, Omnichannel Activation at Indegene, where she led the omnichannel commercialization business organization helping life sciences organizations optimize their field force deployments and commercialization impact. A passionate patient and customer champion, Ms Phelan previously co-led the Transformation Management Office at Novartis and previously was VP, Head, Neuroscience Franchise Patient and Specialty Services, was CEO of Adhera Therapeutics, and held diverse senior leadership positions at Pfizer, Wyeth, Bristol-Myers Squibb, and Schering-Plough. Ms Phelan has served as a member of the board of directors of Achieve Life Sciences (Nasdaq: ACHV) since January 2025, and currently serves on the Audit Committee and the Commercial Committee.

Menassie Taddese MBA is a seasoned veteran of the biopharmaceutical industry with wide ranging experience in general management, finance, business transformation, partnership creation, and overall leadership. He brings over 26 years of experience leading large commercial and cross-functional organizations across the globe to the Medexus board.

Harmony P. Garges MD MPH brings two decades of multinational pharmaceutical leadership experience in the United States and the UK to the Medexus board. Dr Garges has served as Senior Vice President, Chief Global Health Officer at GSK, a biopharma company, since April 2026, where she leads the company's global health function, and as Senior Vice President, Head of Development at GSK from June 2025 to April 2026. She previously served as Chief Medical Officer of ViiV Healthcare, a specialist pharmaceutical company dedicated to HIV medicines and research, from August 2019 to June 2025. In her role at ViiV, Dr Garges was accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr Garges joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across R&D, pharmacovigilance, and medical affairs. During her career, Dr Garges has provided medical leadership for over a dozen new drug applications and new product launches.

Benoit Gravel has 30 years of experience in the pharmaceutical industry from his work at Rhône-Poulenc, Aventis and Sanofi. Mr. Gravel has held several commercial executive positions in Canada, including vice-president diabetes & specialized care patient centered unit at Sanofi. He began his career as an economist in the energy and transportation industries.

Stephen Nelson served as senior vice president, portfolio manager, and investment advisor with TD Wealth Private Investment Advice. Mr. Nelson manages over $6.5 billion in investment assets as of June 2026 and has been a member of TD Waterhouse’s President Club for the past 25 years. He has also served as a director for a number of private companies.